Associations of Preoperative Serum High-density Lipoprotein Cholesterol and Low-density Lipoprotein Cholesterol Levels with the Prognosis of Ovarian Cancer

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2021 Aug 28

PMID 34453586

Citations 8

Authors

Qingqing Lin

Wenchao Liu

Song Xu

Liping Sun

Affiliations

Soon will be listed here.

Abstract

Background: The effect of serum lipids on ovarian cancer is controversial. We conducted this study to evaluate the prognostic value of preoperative plasma lipid profile in patients with ovarian cancer.

Methods: The medical records of 156 epithelial ovarian cancer patients who underwent surgical resection in our department were retrospectively reviewed and analyzed. Serum lipids profiles, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), apolipoprotein A-I (apoA-I), apolipoprotein B (apoB) and clinicopathologic data, were analyzed. Cox proportional hazards regression analyses and Kaplan-Meier method were performed to evaluate the overall survival (OS) and progression-free survival (PFS).

Results: Multivariable Cox regression analysis found that preoperative higher LDL-C level was significantly associated with worse OS (HR 2.088, 95% CI 1.052-4.147, p = 0.035), whereas higher HDL-C level showed significant association with better PFS (HR 0.491, 95% CI 0.247-0.975, p = 0.042). Further Kaplan-Meier survival analysis demonstrated that OS was longer for patients with low levels of LDL-C (< 2.76 mmol/L) compared to those with high levels of LDL-C (≥ 2.76 mmol/L) (P = 0.028), and PFS was better for patients with high levels of HDL-C (≥ 1.19 mmol/L) compared to those with low levels of HDL-C (< 1.19 mmol/L) (P = 0.001).

Conclusions: Preoperative HDL-C and LDL-C levels are significant predictors of clinical outcome in patients with epithelial ovarian cancer.

Citing Articles

Development and validation of a nomogram to predict recurrence in epithelial ovarian cancer using complete blood count and lipid profiles.

Tang X, He J, Huang Q, Chen Y, Chen K, Liu J Front Oncol. 2025; 15:1525867.

PMID: 39963106 PMC: 11830618. DOI: 10.3389/fonc.2025.1525867.

Pre-treatment nutrition-related indicators and the prognosis of patients with newly diagnosed epithelial ovarian cancer: an ambispective cohort study.

Wang S, Zhu J, Wu N, Wang N, Dang X, Zhao M Front Nutr. 2025; 12:1489934.

PMID: 39886546 PMC: 11774736. DOI: 10.3389/fnut.2025.1489934.

Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients.

Peng Q, Zhan C, Shen Y, Xu Y, Ren B, Feng Z BMC Cancer. 2024; 24(1):1549.

PMID: 39695484 PMC: 11657272. DOI: 10.1186/s12885-024-13265-8.

Clinical Value of Nomograms Integrating Circulating Lipid and Inflammation Risk Score in Predicting Long-Term Outcomes After Radical Gastrectomy in Gastric Cancer: A Multicenter Real-World Study.

Hu M, Zheng H, Zheng H, Xu B, Wei L, Xue Z Ann Surg Oncol. 2024; 32(3):2172-2184.

PMID: 39681718 DOI: 10.1245/s10434-024-16687-7.

HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype.

Luo F, Cao J, Chen Q, Liu L, Yang T, Bai X J Immunother Cancer. 2024; 12(6).

PMID: 38871480 PMC: 11177774. DOI: 10.1136/jitc-2023-008146.

References

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Piver M . Treatment of ovarian cancer at the crossroads: 50 years after single-agent melphalan chemotherapy. Oncology (Williston Park). 2006; 20(10):1156, 1158. View

Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E . Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label.... Lancet Oncol. 2013; 14(10):1020-6. DOI: 10.1016/S1470-2045(13)70363-2. View

Perren T, Swart A, Pfisterer J, Ledermann J, Pujade-Lauraine E, Kristensen G . A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484-96. DOI: 10.1056/NEJMoa1103799. View

Burger R, Brady M, Bookman M, Fleming G, Monk B, Huang H . Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26):2473-83. DOI: 10.1056/NEJMoa1104390. View

Armstrong D, Bundy B, Wenzel L, Huang H, Baergen R, Lele S . Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354(1):34-43. DOI: 10.1056/NEJMoa052985. View

Mor G, Alvero A . The duplicitous origin of ovarian cancer. Rambam Maimonides Med J. 2013; 4(1):e0006. PMC: 3678912. DOI: 10.5041/RMMJ.10106. View

Corbet C, Feron O . Emerging roles of lipid metabolism in cancer progression. Curr Opin Clin Nutr Metab Care. 2017; 20(4):254-260. DOI: 10.1097/MCO.0000000000000381. View

Rohrig F, Schulze A . The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016; 16(11):732-749. DOI: 10.1038/nrc.2016.89. View

10.

Faubert B, Solmonson A, DeBerardinis R . Metabolic reprogramming and cancer progression. Science. 2020; 368(6487). PMC: 7227780. DOI: 10.1126/science.aaw5473. View

11.

Ward P, Thompson C . Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21(3):297-308. PMC: 3311998. DOI: 10.1016/j.ccr.2012.02.014. View

12.

Helzlsouer K, Alberg A, Norkus E, Morris J, Hoffman S, Comstock G . Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst. 1996; 88(1):32-7. DOI: 10.1093/jnci/88.1.32. View

13.

Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-Asteriou A . Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem. 2007; 40(15):1129-34. DOI: 10.1016/j.clinbiochem.2007.06.007. View

14.

Li J, Xie H, Li A, Cheng J, Yang K, Wang J . Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry. Oncotarget. 2016; 8(29):46834-46845. PMC: 5564526. DOI: 10.18632/oncotarget.11603. View

15.

Tania M, Khan M, Song Y . Association of lipid metabolism with ovarian cancer. Curr Oncol. 2010; 17(5):6-11. PMC: 2949373. DOI: 10.3747/co.v17i5.668. View

16.

Santos C, Schulze A . Lipid metabolism in cancer. FEBS J. 2012; 279(15):2610-23. DOI: 10.1111/j.1742-4658.2012.08644.x. View

17.

Nam S, Park B, Nam J, Kook M . Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development. Gastrointest Endosc. 2019; 90(3):448-456.e1. DOI: 10.1016/j.gie.2019.04.232. View

18.

Li X, Liu Z, Wu Y, Wu H, Dai W, Arshad B . Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids Health Dis. 2018; 17(1):91. PMC: 5910614. DOI: 10.1186/s12944-018-0745-1. View

19.

Choi Y, Lee D, Han K, Shin C, Kim N . Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer. Eur J Epidemiol. 2018; 33(11):1077-1085. DOI: 10.1007/s10654-018-0440-6. View

20.

Mondul A, Weinstein S, Virtamo J, Albanes D . Serum total and HDL cholesterol and risk of prostate cancer. Cancer Causes Control. 2011; 22(11):1545-52. PMC: 3500884. DOI: 10.1007/s10552-011-9831-7. View